Lowest-Rated StocksLowest-RatedMost-Downgraded StocksMost-DowngradedNASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free SAGE Stock Alerts $11.55 +0.37 (+3.31%) (As of 01:57 PM ET) Add Compare Share Share Today's Range$11.10▼$11.5550-Day Range$11.18▼$20.6152-Week Range$10.92▼$59.99Volume1.68 million shsAverage Volume1.06 million shsMarket Capitalization$695.08 millionP/E RatioN/ADividend YieldN/APrice Target$37.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sage Therapeutics alerts: Email Address Sage Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.12 Rating ScoreUpside/Downside227.5% Upside$37.67 Price TargetShort InterestHealthy16.60% of Float Sold ShortDividend StrengthN/ASustainability-1.66Upright™ Environmental ScoreNews Sentiment0.19Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.53) to ($5.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.41 out of 5 starsMedical Sector115th out of 921 stocksPharmaceutical Preparations Industry42nd out of 419 stocks 4.1 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on 3 buy ratings, 13 hold ratings, and 1 sell rating.Amount of Analyst CoverageSage Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sage Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.60% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Sage Therapeutics has recently decreased by 12.46%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 65.22% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.66. Previous Next 1.2 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sage Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sage Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($6.53) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sage Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama’s Forever Term [exposed]Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here About Sage Therapeutics Stock (NASDAQ:SAGE)Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More SAGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAGE Stock News HeadlinesMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGEMay 14, 2024 | finance.yahoo.comSage Therapeutics, Inc. (SAGE)May 7, 2024 | businesswire.comSage Therapeutics to Participate in Upcoming May Investor ConferencesMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEApril 30, 2024 | finance.yahoo.comSage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call TranscriptApril 28, 2024 | finance.yahoo.comEarnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their EstimatesApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEApril 26, 2024 | finance.yahoo.comSage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 26, 2024 | markets.businessinsider.comBalancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial ReassessmentApril 26, 2024 | markets.businessinsider.comSAGE Therapeutics’ Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold RatingApril 25, 2024 | markets.businessinsider.comHold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline UncertaintyApril 25, 2024 | investorplace.comSAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024April 25, 2024 | seekingalpha.comSage Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationApril 25, 2024 | markets.businessinsider.comSAGE Therapeutics, Inc. Q1 Loss decreases, but misses estimatesApril 25, 2024 | finance.yahoo.comSage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline ProgressApril 25, 2024 | businesswire.comSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressApril 24, 2024 | markets.businessinsider.comHere's what to expect from Sage Therapeutics's earnings reportApril 18, 2024 | msn.comB of A Securities Downgrades Sage Therapeutics (SAGE)April 18, 2024 | markets.businessinsider.comIn-Depth Examination Of 9 Analyst Recommendations For Sage TherapeuticsApril 17, 2024 | msn.comSage Therapeutics stock plunges 20 percent after Parkinson’s drug fails studyApril 17, 2024 | benzinga.comNeurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's DataApril 17, 2024 | msn.comBofA downgrades Sage to underperform, cites failed Parkinson's studyApril 17, 2024 | markets.businessinsider.comNasdaq Down Over 1%; Sage Therapeutics Shares PlungeApril 17, 2024 | finance.yahoo.comSage Stock Collapses To Record Low After Parkinson's Drug Misses Its MarkApril 17, 2024 | investors.comSage Therapeutics Hammered After Parkinson's Drug Misses The MarkSee More Headlines Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/21/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees487Year FoundedN/APrice Target and Rating Average Stock Price Target$37.67 High Stock Price Target$294.00 Low Stock Price Target$14.00 Potential Upside/Downside+233.9%Consensus RatingHold Rating Score (0-4)2.12 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($8.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-541,490,000.00 Net Margins-552.52% Pretax Margin-552.52% Return on Equity-56.81% Return on Assets-51.01% Debt Debt-to-Equity RatioN/A Current Ratio12.22 Quick Ratio12.22 Sales & Book Value Annual Sales$86.46 million Price / Sales7.85 Cash FlowN/A Price / Cash FlowN/A Book Value$13.32 per share Price / Book0.85Miscellaneous Outstanding Shares60,180,000Free Float56,872,000Market Cap$678.83 million OptionableOptionable Beta0.91 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Barry E. Greene (Age 61)President, CEO & Director Comp: $1.29MMs. Kimi E. Iguchi CPA (Age 62)CFO & Treasurer Comp: $665.37kMs. Anne Marie Cook Esq. (Age 62)Senior VP, General Counsel & Secretary Comp: $711.6kMr. Christopher Benecchi (Age 52)Chief Business Officer Comp: $703.76kDr. Laura Gault M.D.Ph.D., Chief Medical OfficerMr. Matt LasmanisChief Technology & Innovation OfficerMr. Mike QuirkChief Scientific OfficerAshley KaplowitzDirector of Investor RelationsMs. Erin E. Lanciani (Age 55)Chief People & Experience Officer Dr. Amy Schacterle Ph.D.Senior Vice President of R&D Strategy and Business ManagementMore ExecutivesKey CompetitorsNuvation BioNYSE:NUVBWave Life SciencesNASDAQ:WVENurix TherapeuticsNASDAQ:NRIXPhibro Animal HealthNASDAQ:PAHCCogent BiosciencesNASDAQ:COGTView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 10,003 shares on 5/20/2024Ownership: 0.017%Walleye Trading LLCSold 14,800 shares on 5/17/2024Ownership: 0.000%Jacobs Levy Equity Management Inc.Sold 187,645 shares on 5/16/2024Ownership: 0.923%Caxton Associates LPSold 64,036 shares on 5/16/2024Ownership: 0.093%California State Teachers Retirement SystemSold 2,791 shares on 5/16/2024Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions SAGE Stock Analysis - Frequently Asked Questions Should I buy or sell Sage Therapeutics stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 1 sell rating, 13 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks. What is Sage Therapeutics' stock price target for 2024? 17 equities research analysts have issued 1 year target prices for Sage Therapeutics' shares. Their SAGE share price targets range from $14.00 to $294.00. On average, they expect the company's stock price to reach $37.67 in the next year. This suggests a possible upside of 227.5% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts. How have SAGE shares performed in 2024? Sage Therapeutics' stock was trading at $21.67 at the start of the year. Since then, SAGE shares have decreased by 46.9% and is now trading at $11.50. View the best growth stocks for 2024 here. When is Sage Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our SAGE earnings forecast. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Thursday, April, 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by $0.17. The biopharmaceutical company earned $7.90 million during the quarter, compared to the consensus estimate of $5.26 million. Sage Therapeutics had a negative net margin of 552.52% and a negative trailing twelve-month return on equity of 56.81%. Sage Therapeutics's quarterly revenue was up 139.4% on a year-over-year basis. During the same quarter last year, the business posted ($2.46) EPS. What ETFs hold Sage Therapeutics' stock? ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) and Virtus LifeSci Biotech Products ETF (BBP).AdvisorShares Dorsey Wright Short ETF (DWSH). What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY). Who are Sage Therapeutics' major shareholders? Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.56%), Bellevue Group AG (7.42%), Price T Rowe Associates Inc. MD (1.35%), Jacobs Levy Equity Management Inc. (0.92%), Baker BROS. Advisors LP (0.68%) and Pinnacle Associates Ltd. (0.48%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SAGE) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account Before It’s Too LateWeiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.